Syndax Pharmaceuticals Inc. | Small-cap | Healthcare
$15.55
-5.01%
| Syndax Stock Comparison:
Syndax vs VertexSyndax vs AlnylamSyndax vs AdaptiveSyndax vs Dyne TherapeuticsSyndax vs Harmony BiosciencesSyndax vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 38.0M
Gross Profit 36.7M 96.63%
Operating Income -69.4M -182.71%
Net Income -71.8M -189.28%
EPS (Diluted) $-0.83

Balance Sheet Metrics

Total Assets 640.7M
Total Liabilities 425.6M
Shareholders Equity 215.1M
Debt to Equity 1.98

Cash Flow Metrics

Operating Cash Flow -95.0M
Free Cash Flow -95.2M

Revenue & Profitability Trend

Syndax Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i23.7M00139.7M1.5M
Cost of Goods Sold i826.0K----
Gross Profit i22.9M----
Gross Margin % i96.5%0.0%0.0%0.0%0.0%
Operating Expenses
Research & Development i241.6M163.0M118.5M88.2M50.4M
Selling, General & Administrative i120.9M66.9M33.3M25.2M22.5M
Other Operating Expenses i-----
Total Operating Expenses i362.5M230.0M151.8M113.5M72.9M
Operating Income i-339.7M-230.0M-151.8M26.2M-71.4M
Operating Margin % i-1,434.4%0.0%0.0%18.8%-4,708.2%
Non-Operating Items
Interest Income i26.1M21.2M5.9M403.0K841.0K
Interest Expense i4.9M208.0K3.1M1.9M2.4M
Other Non-Operating Income-247.0K-361.0K-316.0K202.0K-219.0K
Pre-tax Income i-318.8M-209.4M-149.3M24.9M-73.2M
Income Tax i-----
Effective Tax Rate % i0.0%0.0%0.0%0.0%0.0%
Net Income i-318.8M-209.4M-149.3M24.9M-73.2M
Net Margin % i-1,346.1%0.0%0.0%17.8%-4,822.5%
Key Metrics
EBITDA i-313.8M-209.1M-146.2M26.9M-70.7M
EPS (Basic) i$-3.72$-2.98$-2.46$0.48$-1.87
EPS (Diluted) i$-3.72$-2.98$-2.46$0.48$-1.87
Basic Shares Outstanding i8562206570370519607609065206480941308242
Diluted Shares Outstanding i8562206570370519607609065206480941308242

Income Statement Trend

Syndax Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i154.1M295.4M74.4M222.0M115.2M
Short-term Investments i428.8M282.2M410.0M224.9M177.8M
Accounts Receivable i7.6M03.5M0-
Inventory i366.0K----
Other Current Assets612.0K63.0K117.0K150.0K341.0K
Total Current Assets i603.1M580.9M489.8M448.4M298.9M
Non-Current Assets
Property, Plant & Equipment i2.1M1.6M1.1M1.4M546.0K
Goodwill i-----
Intangible Assets i-----
Long-term Investments-----
Other Non-Current Assets217.0K680.0K922.0K-1.3M
Total Non-Current Assets i121.8M32.0M7.4M1.3M1.7M
Total Assets i724.8M612.9M497.2M449.7M300.6M
Liabilities
Current Liabilities
Accounts Payable i11.6M17.2M4.4M5.7M3.5M
Short-term Debt i12.6M1.0M439.0K362.0K2.6M
Current Portion of Long-term Debt-----
Other Current Liabilities1.3M888.0K604.0K1.9M528.0K
Total Current Liabilities i103.5M58.1M29.1M20.7M18.9M
Non-Current Liabilities
Long-term Debt i333.1M588.0K722.0K20.6M17.9M
Deferred Tax Liabilities i-----
Other Non-Current Liabilities----1.0K
Total Non-Current Liabilities i333.1M588.0K722.0K20.6M29.6M
Total Liabilities i436.7M58.7M29.8M41.3M48.4M
Equity
Common Stock i9.0K8.0K7.0K6.0K5.0K
Retained Earnings i-1.2B-902.4M-693.0M-543.7M-568.6M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i288.1M554.2M467.4M408.4M252.2M
Key Metrics
Total Debt i345.7M1.6M1.2M21.0M20.5M
Working Capital i499.5M522.8M460.7M427.7M280.0M

Balance Sheet Composition

Syndax Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i-318.8M-209.4M-149.3M24.9M-73.2M
Depreciation & Amortization i8.0K12.0K33.0K43.0K89.0K
Stock-Based Compensation i43.0M31.0M16.0M13.3M9.1M
Working Capital Changes i2.5M16.3M-8.3M-11.0M-4.2M
Operating Cash Flow i-272.2M-161.3M-140.0M27.5M-67.4M
Investing Activities
Capital Expenditures i00225.0K-129.0K0
Acquisitions i-----
Investment Purchases i-557.1M-354.6M-495.3M-294.7M-278.9M
Investment Sales i337.3M472.2M308.9M254.0M136.4M
Investing Cash Flow i-219.8M117.6M-186.2M-40.9M-142.5M
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i--0019.7M
Debt Repayment i00-21.0M00
Financing Cash Flow i343.7M258.1M160.4M86.9M297.8M
Free Cash Flow i-274.9M-160.6M-133.7M29.0M-71.3M
Net Change in Cash i-148.3M214.4M-165.8M73.5M87.9M

Cash Flow Trend

Syndax Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -4.18
Forward P/E -4.39
Price to Book 8.50
Price to Sales 17.19
PEG Ratio -1.11

Profitability Ratios

Profit Margin 96.51%
Operating Margin -182.71%
Return on Equity -113.22%
Return on Assets -39.50%

Financial Health

Current Ratio 4.71
Debt to Equity 219.49
Beta 0.72

Per Share Data

EPS (TTM) $-3.89
Book Value per Share $1.83
Revenue per Share $0.91

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
sndx1.3B-4.188.50-113.22%96.51%219.49
Vertex 101.2B28.085.8922.77%31.86%8.89
Alnylam 61.1B-213.71244.95-257.83%-12.96%1,093.31
Adaptive 1.9B-11.6810.68-57.60%-59.07%121.39
Dyne Therapeutics 1.9B-3.902.63-61.32%0.00%21.19
Harmony Biosciences 1.9B10.452.4127.58%23.42%22.43

Financial data is updated regularly. All figures are in the company's reporting currency.